Dr. Purnanand Duddu Sarma Net Worth

The estimated Net Worth of Purnanand D Sarma is at least $809 Thousand dollars as of 25 May 2021. Dr Sarma owns over 10,500 units of Immunome stock worth over $151,830 and over the last 3 years he sold IMNM stock worth over $0. In addition, he makes $657,442 as Pres and CEO & Director at Immunome.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dr Sarma IMNM stock SEC Form 4 insiders trading

Dr has made over 1 trades of the Immunome stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,500 units of IMNM stock worth $193,305 on 25 May 2021.

The largest trade he's ever made was buying 10,500 units of Immunome stock on 25 May 2021 worth over $193,305. On average, Dr trades about 2,625 units every 0 days since 2021. As of 25 May 2021 he still owns at least 10,500 units of Immunome stock.

You can see the complete history of Dr Sarma stock trades at the bottom of the page.

Dr. Purnanand Duddu Sarma biography

Dr. Purnanand Duddu Sarma is the Pres, CEO & Director at Immunome.

What is the salary of Dr Sarma?

As the Pres and CEO & Director of Immunome, the total compensation of Dr Sarma at Immunome is $657,442. There are no executives at Immunome getting paid more.

How old is Dr Sarma?

Dr Sarma is 56, he's been the Pres and CEO & Director of Immunome since . There are 2 older and 1 younger executives at Immunome. The oldest executive at Immunome, Inc. is Dr. Dennis H. Giesing, 69, who is the Chief Devel. Officer.

What's Dr Sarma's mailing address?

Purnanand's mailing address filed with the SEC is C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON, PA, 19341.

Insiders trading at Immunome

Over the last 4 years, insiders at Immunome have traded over $0 worth of Immunome stock and bought 480,004 units worth $5,722,735 . The most active insiders traders include Clay B Siegall, Jean Jacques Bienaime, and Michael Rapp. On average, Immunome executives and independent directors trade stock every 84 days with the average trade being worth of $518,362. The most recent stock trade was executed by Jean Jacques Bienaime on 15 August 2024, trading 7,000 units of IMNM stock currently worth $97,580.

What does Immunome do?

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Complete history of Dr Sarma stock trades at Immunome

Immunome executives and stock owners

Immunome executives and other stock owners filed with the SEC include:

• Dr. Purnanand Duddu Sarma,
  Pres, CEO & Director
• Sandra G. Stoneman Esq.,
  Chief Legal Officer, Gen. Counsel & Corp. Sec.
• Dr. Michael J. Morin Ph.D.,
  Chief Scientist
• Dr. Scott K. Dessain M.D., Ph.D.,
  Co-founder & Chairman of the Scientific Advisory Board
• Dr. Dennis H. Giesing,
  Chief Devel. Officer
• Matthew K. Robinson Ph.D.,
  Sr. VP of R&D
• Corleen M. Roche,
  Chief Financial Officer
• Michael Widlitz,
  Director
• Michael Lefenfeld,
  Director
• Dennis H Giesing,
  Chief Development Officer
• Jean Jacques Bienaime,
  
• Max Rosett,
  EVP, Operations & CFO
• James P Boylan,
  
• Philip Tsai,
  Chief Technology Officer
• Franklyn G Prendergast,
  Director
• Sandra M Swain,
  
• I Wistar Iii Morris,
  10% owner
• Richard F Fitzgerald,
  Chief Financial Officer
• John L Lamattina,
  Director
• Michael Rapp,
  Director
• Corleen M. Roche,
  Chief Financial Officer
• Philip Wagenheim,
  
• Richard A Baron,
  Director
• Matthew K Robinson,
  Chief Technology Officer
• Purnanand D Sarma,
  President and CEO
• Clay B Siegall,
  President and CEO
• Isaac Barchas,
  
• Phil Noland Roberts,
  Chief Technology Officer
• Carol Schafer,
  
• Kinney Horn,
  CHIEF BUSINESS OFFICER
• Jack Higgins,
  Chief Scientific Officer
• Robert Lechleider,
  Chief Medical Officer
• Bruce Turner,
  Chief Strategy Officer